The Europe CDMO market was valued at USD 70.86 Billion in 2025, driven by rising chronic disease prevalence and strategic industry mergers across the region. The market is anticipated to grow at a CAGR of 9.80% during the forecast period of 2026-2035, with the values likely to reach USD 180.48 Billion by 2035.
Base Year
Historical Period
Forecast Period
According to the International Diabetes Federation, Europe’s diabetes prevalence, around 9.8%, is projected to rise by 10% by 2050, significantly driving demand for CDMO services to support the production of diabetes-related therapeutics and treatments.
In October 2024, ROVI, a European pharmaceutical company decided to retain its CDMO business after a strategic review, focusing on expanding sterile fill & finish capacity. This move is expected to strengthen market competitiveness and fuel regional CDMO market growth in Europe.
A notable market trend is the rise of agile, mid-sized CDMOs addressing complex pharma needs. For instance, in April 2025, Meribel Pharma Solutions launched with 13 European sites to deliver specialized, end-to-end development and manufacturing services.
Compound Annual Growth Rate
9.8%
Value in USD Billion
2026-2035
*this image is indicative*
Contract development and manufacturing organizations (CDMOs) offer end-to-end solutions for the pharmaceutical industry by managing complex processes such as formulation, analytical testing, and large-scale production. They enable companies to focus on innovation while ensuring regulatory compliance and operational efficiency. The CDMO market in Europe is advancing steadily, propelled by the surge in biologics, biosimilars, and advanced therapies. The region benefits from a robust scientific ecosystem, strict regulatory standards, and growing demand for flexible, high-quality manufacturing. The market was valued at USD 70.86 Billion in 2025, reflecting increased outsourcing by both large pharmaceutical firms and emerging biotech across Europe.
Increasing Cancer Prevalence to Boost Market Growth
One major growth driver in the market is the increasing cancer burden, which has amplified the demand for specialized pharmaceutical development. For instance, according to the European Commission, 1 in every 20 Europeans has received a cancer diagnosis during their lifetime, underlining a pressing need for targeted drug formulation and production capabilities. CDMOs are increasingly collaborating with pharmaceutical companies to accelerate the development of oncological therapies, offering advanced solutions such as customized formulations and specialized delivery systems. This surge in disease prevalence continues to fuel the expansion of CDMO services across Europe.
Increasing Mergers to Meet Rising Europe CDMO Market Demand
Strategic mergers and cross-regional collaborations are another critical growth catalyst for the European CDMO sector. For instance, in July 2024, MedPharm Ltd. (UK) merged with Tergus Pharma (US) to form a global leader in topical and transepithelial CDMO services. The combined entity now provides integrated development-to-commercial production solutions from facilities in both the UK and US. This merger expands access to cutting-edge manufacturing, clinical trial capabilities, and in vitro testing for European clients. Such alliances enhance regional capacity and drive innovation, making Europe a competitive hub for contract pharmaceutical development.
The market is witnessing several trends, including strategic alliances between affluent companies in the region.
Rising Strategic Collaborations Between Leading Companies and Emerging Startups to Impact Market Value Positively
A major market trend is the rise in strategic alliances, reshaping the European market landscape. For instance, in December 2024, the European Commission approved Novo Holdings’ acquisition of Catalent without conditions, affirming that the deal does not pose competition concerns within the European Economic Area. This move highlights the increasing integration of pharmaceutical giants with specialized CDMOs, strengthening production capabilities. Such consolidations are poised to enhance market competitiveness and drive long-term growth.
Based on Service Type Contract Manufacturing Organization to Witness Substantial Growth
As Europe’s pharmaceutical landscape evolves, the demand for streamlined, efficient, and specialized outsourcing solutions has never been higher. The market is divided into contract manufacturing organizations (CMOs) and contract research organizations (CROs) service types. These segments collectively support pharmaceutical and biotech firms by offering end-to-end manufacturing and research services. Among these, contract manufacturing organizations are poised to dominate the market landscape. According to EMR estimates, the CMO segment grew from USD 26.78 billion in 2018 to USD 42.94 billion by 2024, driven by an increasing drug complexity and treatment innovations. Forecasts indicate a continued upward trajectory, with the segment expected to reach USD 107.07 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.0% during the forecast period.
The CDMO market report covers Germany, the United Kingdom, France, Italy, and other regional markets. Among these, Germany is anticipated to dominate, owing to its advanced pharmaceutical manufacturing capabilities, strong regulatory environment, and strategic investments. Notably, in October 2024, Rentschler Biopharma announced its largest-ever investment at its Laupheim headquarters, launching construction of a state-of-the-art buffer media facility. This expansion aims to modernize infrastructure, increase production efficiency, and strengthen Germany’s position in the global biopharmaceutical landscape.
The Europe CDMO market research report by Expert Market Research provides an in-depth analysis of the competitive landscape, offering key insights into grants, funding trends, investments, and strategic initiatives by major players. It highlights key patents related to small-molecule drug development and manufacturing, and tracks recent investments, mergers, acquisitions, and partnerships that showcase the market's growth trajectory. Additionally, the report details strategic activities by leading companies, including regional expansions, adoption of new technologies, and efforts to enhance capacity, helping stakeholders better understand the market dynamics and positions of key industry players. Some of the leading players are as follows:
Vetter Pharma stands out as CDMO specializing in aseptic filling for injectables. Known for its full-service approach, the company assists clients from early-stage formulation to market-ready production. With cutting-edge sterile manufacturing infrastructure across Europe, Vetter offers support in device integration, analytical development, and regulatory preparation, helping pharmaceutical firms deliver complex parenteral drugs with precision and compliance.
Recipharm, headquartered in Stockholm, Sweden, delivers comprehensive manufacturing solutions covering oral, injectable, and biologic drugs. In October 2024, it partnered with Exela Pharma Sciences, adding significant production capacity for injectables, including GLP-1s and ADCs. Their modular sterile line in Germany enhances capabilities for pre-filled syringes and vials, strengthening support for biotechs through clinical and early commercial stages with high-grade aseptic technologies.
Patheon, part of Thermo Fisher Scientific, offers versatile CDMO services encompassing APIs, biologics, injectables, and advanced modalities like plasmids and viral vectors. With facilities across the U.S., it partners with industry giants, such as Merck and Amgen, to streamline development and commercial scale-up. Known for agility and compliance, Patheon’s integrated approach supports seamless drug progression under cGMP from concept to global distribution.
Pfizer’s CDMO unit, Pfizer CentreOne, leverages its extensive manufacturing ecosystem to offer solutions in oral solid dose forms, sterile injectables, and biologics. Active in Europe’s outsourcing landscape, it combines technical expertise with global regulatory know-how. Pfizer CentreOne supports partners through drug development, scaling, and commercial supply, enabling the timely and reliable delivery of therapeutics with proven quality systems and global reach.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Boehringer Ingelheim, Famar SA, Lonza Group, LTS Lohmann Therapie-Systeme AG, Aenova Holding GmBH, Fareva SA, FUJIFILM Diosynth Biotechnologies, eXmoor Pharma concepts limited, B. Braun SE, and Sanofi CDMO.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Therapeutic Area
Market Breakup by End User
Market Breakup by Region
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share